Pieris Pharmaceuticals Inc (PIRS)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Stephen S. Yoder |
| Employees: | 140 |
| Web site: | pieris.com |
|
225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110
857-246-8998
| |
-
Formally known as:
- MARIKA, INC COMMON STOCK
- PIERIS PHARMACEUTICALS INC COM
- PIERIS PHARMACEUTICALS INC COM
| Date | Ratio |
|---|---|
| 2024-04-23 | 1:80 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Pieris Pharmaceuticals, Inc. develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases. The company also develops a 4-1BB/ HER2 bispecific program addressing undisclosed targets for immuno-oncology diseases.
Please log in first to see chart